<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-14004411</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-02-23</date_registration>
      <primary_sponsor>Taihe Hospital, Hubei University of Medicine</primary_sponsor>
      <public_title>The effects of Umbilical cord blood stem cells in treatment of patients with decompensated HBV-associated live cirrhosis: a randomized controlled trial</public_title>
      <acronym />
      <scientific_title>The effects of Umbilical cord blood stem cells in treatment of patients with decompensated HBV-associated live cirrhosis: a randomized controlled trial</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-03-01</date_enrolment>
      <type_enrolment />
      <target_size>Treatment group:30;Control group:30;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=5159</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Other</phase>
      <hc_freetext>Liver cirrhosis</hc_freetext>
      <i_freetext>Treatment group:Umbilical cord blood stem cells;Control group:0.9% Sodium chloride containing 1% Human Albumin;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhongji Meng</firstname>
        <middlename />
        <lastname />
        <address>32 South Renmin Road, Shiyan Hubei, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 071 98801821</telephone>
        <email>zhongji.meng@163.com</email>
        <affiliation>Taihe Hospital, Hubei University of Medicine</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhongji Meng</firstname>
        <middlename />
        <lastname />
        <address>32 South Renmin Road, Shiyan Hubei, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 071 98801821</telephone>
        <email>zhongji.meng@163.com</email>
        <affiliation>Taihe Hospital, Hubei University of Medicine</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. A history of chronic HBV infection;
2. Ultrasonographic evidence of LC;
3. HBV DNA &gt;100 IU/ ml;
4. CTP Score more than 7.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. The presence of HCC and any underlying neoplasm; 
2. Liver failure (TBil&gt;10 ULN, PTA&lt;40%);
3. A history of variceal bleeding 2 months prior to the enrolment; 
4. The presence of severe comorbidities; 
5. Coinfection with HAV, HCV, HDV, HEV, HIV, etc;
6. Evidence of extrahepatic biliary diseases;
7. The presence of hepatic, portal, or splenic vein thromboses on Doppler ultrasonography; 
8. Active substance abuse; 
9. A history of nucleot(s)ides administration 6 months prior to the enrolment;
10. Unwillingness to sign the informed consent form.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Liver function;liver stiffnes;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>HBV DNA;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Science and technology department of Hubei Province</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-01-20</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>